New Research on ImmunoPrecise Antibodies Ltd (IPA-NASDAQ/IPA-TSX)

Posted by Karen Goldfarb

May 18, 2022 at 11:06 AM

An Executive Informational Overview (EIO) is now available on ImmunoPrecise Antibodies Ltd, a full-service contract research organization (CRO) for therapeutic antibody discovery and development. The 72-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download ImmunoPrecise Antibodies Ltd Initiation Report

Read More

Topics: biotech, biopharmaceuticals, biotechnology, Oncology, Biologics, Humanized monoclonal antibodies, Immunoassay, Immunogen, Monoclonal antibody, Antibody, Contract research organization (CRO), Customer relationship management (CRM), Human monoclonal antibodies, SARS-CoV-2, Polyclonal antibody, Contract manufacturing organization (CMO), Enterprise resource planning (ERP)

April 2022 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

April 29, 2022 at 1:23 PM

Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19

March 2022 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

March 14, 2022 at 6:22 PM

Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19

New Research Released on FSD Pharma Inc. (HUGE-NASDAQ/HUGE-CSE)

Posted by Karen Goldfarb

March 10, 2022 at 12:14 PM

An Executive Informational Overview (EIO) is now available on FSD Pharma Inc., a biopharmaceutical company focused on developing innovative therapies for brain and inflammatory disorders to improve patient quality of life. The 58-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download FSD Pharma Inc.  Initiation Report

Read More

Topics: biotech, biopharmaceuticals, biotechnology, neurodegenerative, multiple sclerosis, inflammatory, MS, major depressive disorder (MDD), myelin degradation, bipilar disorder

New Research on Victory Square Technologies Inc. (VSQTF-OTCQX, VST-CSE)

Posted by Karen Goldfarb

January 13, 2022 at 12:01 PM

An Executive Informational Overview (EIO) is now available on Victory Square Technologies Inc., a publicly-traded company headquartered in Vancouver, Canada, and listed on the Canadian Securities Exchange (VST), Frankfurt Exchange (6F6), and the OTCQX (VSQTF). The Company builds, acquires, and invests in promising startups, then provides the senior leadership with resources in which to fast-track a company’s growth, resulting in rapid scale-up and monetization. Victory Square’s sweet spot is the innovative technology that is shaping the Fourth Industrial Revolution, where boundaries are being blurred between the physical, digital, and biological worlds. The 76-page report details the Company's business and key sectors of focus, profiles its 20+ investees, as well as details its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download Victory Square Technologies Inc.  Initiation Report

Read More

Topics: artificial intelligence (AI), Augmented reality, Electronic medical records, Fourth Industrial Revolution, Internet of Things, Metaverse, Non-fungible tokens, Web 3.0, Victory Square Technologies, Creator Economy, Software-as-a-Service, Saas, Solar photovoltaic, Unicorn company, Virtual reality

New Research Released on Emerald Health Pharmaceuticals (CLOSELY-HELD)

Posted by Karen Goldfarb

November 30, 2021 at 6:22 PM

An Executive Informational Overview (EIO) is now available on Emerald Health Pharmaceuticals Inc., a closely-held clinical-stage biotechnology company developing novel proprietary therapeutic molecules to treat various neurodegenerative, autoimmune, inflammatory, and fibrotic diseases with no current cure. The 74-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download Emerald Health Pharmaceuticals Initiation Report

Read More

Topics: biotech, biopharmaceuticals, biotechnology, neurodegenerative, fibrotic, multiple sclerosis, Huntingtons Disease, cannabigerol, SSc, inflammatory, systemic sclerosis, MS, Parkinsons Disease, cannabinoids, cannabidiol

November 2021 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

November 17, 2021 at 9:28 AM

Crystal Research Associates has issued a 13-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

GeoVax Enters Agreement with PNP Therapeutics for Solid Tumor Treatment

Posted by Karen Goldfarb

October 4, 2021 at 11:13 AM

Crystal Research Associates has issued a 6-page update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ) following its announcement of an Assignment and License Agreement with PNP Therapeutics, Inc. (“PNP”), granting GeoVax exclusive rights to develop and commercialize Gedeptin®, a novel patented product to treat solid tumors. 

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

August 2021 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

August 15, 2021 at 6:35 PM

Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

May 2021 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

May 11, 2021 at 3:59 PM

Crystal Research Associates has issued an 16-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

March 2021 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

March 29, 2021 at 2:53 PM

Crystal Research Associates has issued an 14-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

February 2021 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

February 16, 2021 at 10:13 AM

Crystal Research Associates has issued an 11-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

 

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

New Research Released on Celsion Corporation (CLSN-NASDAQ)

Posted by Karen Goldfarb

December 9, 2020 at 3:35 PM

An Executive Informational Overview (EIO) is now available on Celsion Corporation, a fully integrated biopharmaceutical company focused on developing cancer therapies for difficult-to-treat forms of cancers. The 68-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download Celsion Corporation  Initiation Report

Read More

Topics: biotech, immunotherapy, cancer, autoimmune, hepatocellular cancer, GEN-1, ovarian cancer, interleukin-12, IL-12, ThermoDox, primary liver cancer, celsion

November 2020 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

November 11, 2020 at 10:24 AM

Crystal Research Associates has issued a 12-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-NASDAQ).

 

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

UPDATED BASE REPORT on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

October 21, 2020 at 6:14 PM

Crystal Research Associates has issued an 84-page Updated Executive Informational Overview (EIO) on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-NASDAQ), detailing the Company's recent news and developments, anticipated clinical trial and regulatory filing milestones, and financial position. The report is available for download below.

Download GeoVax Labs, Inc.  Updated Base Report 10-21-2020

Read More

Topics: geovax

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Date

see all

Posts by Topic